Novel antidepressants and panic disorder: Evidence beyond current guidelines

Neuropsychobiology

Volumn 63, Issue 1, 2010, Pages 1-7

  Serretti, Alessandro ^a   Chiesa, Alberto ^a   Calati, Raffaella ^a   Perna, Giampaolo ^b,d   Bellodi, Laura ^c   De Ronchi, Diana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b San Benedetto Hospital   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Duloxetine; Milnacipran; Mirtazapine; Panic disorder; Reboxetine

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BROMAZEPAM; CITALOPRAM; CLONAZEPAM; DULOXETINE; FLUOXETINE; LORAZEPAM; MILNACIPRAN; MIRTAZAPINE; OXAZEPAM; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; AGITATION; AGORAPHOBIA; ANXIETY; ANXIETY DISORDER; APATHY; APPETITE; BLURRED VISION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DROWSINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; KNOWLEDGE BASE; LOW DRUG DOSE; MAJOR DEPRESSION; MEDLINE; MICTURITION DISORDER; MYALGIA; NAUSEA; NERVOUSNESS; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLISHING; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; TREMOR; URINE HESITATION; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; HUMANS; MIANSERIN; MORPHOLINES; PANIC DISORDER; PRACTICE GUIDELINES AS TOPIC; THIOPHENES;

EID: 77957991946     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321831     Document Type: Review

References (55)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, American Psychiatric Association, 1994.
2. Roy-Byrne PP, Craske MG, Stein MB: Panic disorder. Lancet 2006; 368:1023-1032.
3. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia: Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust NZ J Psychiatry 2003; 37: 641-656.
4. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP: WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 2003; 8:17-30. (Pubitemid 38419778)
5. American Psychiatric Association: Treatment of Patients with Panic Disorder ed 2. Washington, APA, 2009.
6. Westra H, Stewart S, Conrad B: Naturalistic manner of benzodiazapine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anx Disord 2002; 16: 233-246.
7. Coplan JD, Lydiard RB: Brain circuits in panic disorder. Biol Psychiat r y 1998; 44: 1264-1276.
8. Kjernisted K, McIntosh D: Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag 2007; 3: 59-69.
9. De Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(suppl 4):19-25.
10. Dugan SE, Fuller MA: Duloxetine: a dual reuptake inhibitor. Ann Pharmacother 2004; 38:2078-2085.
11. Rogoz Z, Skuza G, Maj J: Pharmacological profile of milnacipran, a new antidepressant, given acutely. Pol J Pharmacol 1999; 51: 317-322.
12. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH: The selective norepi-nephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004; 10 : 23-4 4.
13. Jadad AR, Moore RA, Carroll D: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials 1996; 17:1-12.
14. Wells GA, Shea B, O'Connell D: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2005. http://www.ohri.ca/pro-grams/clinical-epidemiology/oxford.htm.
15. De Montigny C, Haddjeri N, Mongeau R, Blier P: The effects of mirtazapine on the interactions between central noradrenergic and serotoninergic systems. CNS Drugs 1995; 4: 13-17.
16. Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267-285.
17. San L, Arranz B: Mirtazapine: only for depression? Acta Neuropsychiatr 20 06; 18 : 130-143.
18. Carpenter LL, Leon Z, Yasmin S, Price LH: Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81- 8 6 .
19. Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA: The effect of mirtazapine in panic disorder: an open-label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 2001; 16 : 363-368.
20. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
21. Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 1973; 9: 13-28.
22. Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S: Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry 2002; 59: 661-662.
23. Ilies-Alexandru D, Zaharia C: Clinical considerations on mirtazapine treatment in depression-panic disorder comorbidity. Europ Neuropsychopharm 2002; 12: 42.
24. Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G: Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003; 18 : 35-38.
25. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34: 1303-1307.
26. Montañes-Rada F, Bilbao-Garay J, de Lucas-Taracena MT, Ortiz-Ortiz ME: Venlafaxine, serotonin syndrome, and differential diagnoses. J Clin Psychopharmacol 2005; 25: 101-102.
27. Brunello N, Racagni G: Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998; 13: 13-19.
28. Schatzberg AF: Clinical efficacy of rebox-etine in major depression. J Clin Psychiatry 2000; 61(suppl 10):31-38 .
29. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M: Rebox-etine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002; 63:31-37.
30. Dannon PN, Iancu I, Grunhaus L: The efficacy of reboxet ine in the treat ment-refracto-ry patients with panic disorder: an open-label study. Hum Psychopharmacol 2002; 17: 329-333.
31. 2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psy-chopharmacol 2004; 24:277-282.
32. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ: Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 2003; 18 : 279-284.
33. Bertani A, Perna G, Migliarese G, Di Pas-quale D, Cucchi M, Caldirola D, Bellodi L: Comparison of the treatment with parox-etine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsy-chiatry 2004; 37: 206-210.
34. Preskorn SH: Milnacipran: a dual norepi-nephrine and serotonin reuptake pump inhibitor. J Psychiatr Pract 2004; 10:119-126.
35. Bisserbe JC: Clinical utility of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 2002; 17(suppl 1): S43-S50.
36. Cia H, Brizuela J, Cascardo E, Varela M: Clonazepam and milnacipran in the treatment of patients with panic disorder and co-morbid depression. Prim Care Community Psychiatry 2006; 11: 51-56.
37. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG: The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol 2007; 22:153-158.
38. Bakker A, van Balkom AJ, Spinhoven P: SSRIs versus TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002; 106:163-167.
39. Gupta S, Nihalani N, Masand P: Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. A nn Clin Psychiatry 2007; 19: 125-132.
40. Rabasseda X: Duloxetine: a new serotonin/ noradrenaline reuptake inhibitor for the treatment of depression. Drugs Today (Barc) 2004; 40:773-790.
41. Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH: Open-label support for dulox-etine for the treatment of panic disorder. CNS Neurosci Ther 2009; 15: 19-23.
42. Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998; 18 : 12S-18S.
43. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mir-tazapine. CNS Drug Rev 2001; 7:249-264.
44. Tanum L: Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000; 402: 37-40.
45. Nakagawa A, Watanabe N, Omori IM, Bar-bui C, Cipriani A, McGuire H, Churchill R, Furukawa TA: Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antide-pressants: a systematic review and meta-analysis. CNS Drugs 2008; 22: 587-602.
46. Khouzam HR: The antidepressant nefazo-done: a review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration. J Psychosoc Nurs Ment Health Serv 2000; 38:20-25.
47. Wilkes S: Bupropion. Drugs Today (Barc) 2006; 42:671-681.
48. Serretti A, Chiesa A: Treatment-emergent sexual dysfunction related to antidepres-sants: a meta-analysis. J Clin Psychopharma-col 2009; 29:259-266.
49. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; 62(suppl 3):10-21.
50. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 20 01; 158: 1989 -1992 .
51. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24:1-14.
52. Hamilton SP, Haghighi F, Heiman GA, Klein DF, Hodge SE, Fyer AJ, Weissman MM, Knowles JA: Investigation of dopamine receptor (DRD4) and dopamine transporter (DAT) polymorphisms for genetic linkage or association to panic disorder. Am J Med Genet 2000; 96:324-330.
53. Esposito E: Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 2006; 7:177-185.
54. Lydiard RB: The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64(suppl 3):21-27.
55. Gao K, Muzina D, Gajwani P, Calabrese JR: Efficacy of typical and atypical antipsychot-ics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67: 1327-1340.